Protagenic Therapeutic -CW25PTIXWPreferred / convertible
13F holders, Q1 2025 (March 31)6holders
1new positions
1sold out
$0.01avg. 13F price*
At the end of Q1 2025, 6 institutions reported holding Protagenic Therapeutic -CW25 (PTIXW) in their 13F filings, unchanged from Q4 2024. 1 opened new positions and 1 sold out. The largest holders were Warberg Asset Management LLC ($1K), Clear Street LLC ($750) and Susquehanna International Group, LLP ($376).
- Company
- Protagenic Therapeutic -CW25
- CUSIP
- 74365N111
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $750 |
| Exits | 1 | $61 |
All 13F filers, Q4 2024 → Q1 2025: 102,640 shares bought and 36,739 shares sold, net +65,901 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| Warberg Asset Management LLC | — | No change | 170,242 | $1K |
| Clear Street LLC | — | New | 100,000 | $750 |
| Susquehanna International Group, LLP | — | Reduce -25.3% | 50,184 | $376 |
| GTS Securities LLC | — | Reduce -0.4% | 25,300 | $202 |
| UBS Group AG | — | Add +733.3% | 3,000 | $21 |
| HRT Financial LP | — | Reduce -9.7% | 20,119 | $0 |
"% of holder's portfolio" is PTIXW's weight in each manager's 13F, not the share of Protagenic Therapeutic -CW25 the manager owns.